FindTrial
Sign In

Expression of DCXR in Breast Cancer and Its Clinicopathological Significance and Mechanisms

Expression of DCXR in Breast Cancer and Its Clinicopathological Significance and Mechanisms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125007
Enrollment
Unknown
Registered
2026-05-20
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Breast cancer group:None

Sponsors

Fuding Hospital,Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. all patients were diagnosed as breast cancer by surgical resection and pathology; 2. the clinical data and follow-up data are complete; 3. approved by the hospital ethics society.

Exclusion criteria

Exclusion criteria: 1. patients with incomplete clinical data; 2. complicated with tumors in other parts.

Design outcomes

Primary

MeasureTime frame
DCXR?ER?PR?Her-2?Ki67?E-cadherin? p120?N-cadherin?ß-catenin;—

Countries

China

Contacts

Public ContactPeipei Xia

Fuding Hospital,Fujian University of Traditional Chinese Medicine

120535351@qq.com+86 593 7832720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026